Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2018 Dec 27:11:317-322.
doi: 10.2147/CMAR.S182091. eCollection 2019.

Long-term survival after percutaneous irreversible electroporation of inoperable colorectal liver metastases

Andreas Schicho  1 , Christoph Niessen  1 , Michael Haimerl  1 , Isabel Wiesinger  1 , Christian Stroszczynski  1 , Lukas P Beyer  1 , Philipp Wiggermann  2
Affiliations

Long-term survival after percutaneous irreversible electroporation of inoperable colorectal liver metastases

Andreas Schicho et al. Cancer Manag Res. .

Abstract

Background: For colorectal liver metastases (CRLM) that are not amenable to surgery or thermal ablation, irreversible electroporation (IRE) is a novel local treatment modality and additional option.

Methods: This study is a retrospective long-term follow-up of patients with CRLM who underwent IRE as salvage treatment.

Results: Of the 24 included patients, 18 (75.0%) were male, and the median age was 57 (range: 28-75) years. The mean time elapsed from diagnosis to IRE was 37.9±37.3 months. Mean overall survival was 26.5 months after IRE (range: 2.5-69.2 months) and 58.1 months after diagnosis (range: 14.8-180.1 months). One-, three-, and five-year survival rates after initial diagnosis were 100.0%, 79.2%, and 41.2%; after IRE, the respective survival rates were 79.1%, 25.0%, and 8.3%. There were no statistically significant differences detected in survival after IRE with respect to gender, age, T- or N-stage at the time of diagnosis, size of metastases subject to IRE, number of hepatic lesions, or time elapsed between IRE and diagnosis.

Conclusion: For nonresectable CRLM, long-term survival data emphasize the value of IRE as a new minimally invasive local therapeutic approach in multimodal palliative treatment, which is currently limited to systemic or regional therapies in this setting.

Keywords: CRLM; colorectal cancer; irreversible electroporation; liver metastases; long-term; salvage treatment; survival.

PubMed Disclaimer

Conflict of interest statement

Disclosure The authors report no conflicts of interest in this work.

Figures

Figure 1
Figure 1
Kaplan–Meier survival curves based on tumor characteristics. Notes: There were no statistically significant differences comparing T- and N-stage at the time of diagnosis or number of CRLM at the time of IRE. (A) T1/2 and T3/4. (B) N0, N1, and N2. (C) One or more than one (2+) hepatic metastases. Abbreviations: CRLM, colorectal liver metastases; IRE, irreversible electroporation.
Figure 2
Figure 2
Kaplan–Meier survival curves based on patient characteristics. Notes: No statistically significant difference was detected between gender and age. (A) Female (F) and male (M). (B) Young (Y) and old (O) patients, split by the median.
Figure 3
Figure 3
Kaplan–Meier survival curves based on IRE treatment characteristics. Notes: Comparison of size of CRLM subjected to IRE and time of IRE after diagnosis, no statistically significant difference was found. (A) Size of the treated metastasis (smaller vs ≥2 cm). (B) Early (E) or late (L) IRE, split by the median. Abbreviations: CRLM, colorectal liver metastases; IRE, irreversible electroporation.
See this image and copyright information in PMC

References

    1. Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A. Global cancer statistics, 2012. CA Cancer J Clin. 2015;65(2):87–108. - PubMed
    1. Bosetti C, Levi F, Rosato V, et al. Recent trends in colorectal cancer mortality in Europe. Int J Cancer. 2011;129(1):180–191. - PubMed
    1. Edwards BK, Noone AM, Mariotto AB, et al. Annual report to the nation on the status of cancer, 1975–2010, featuring prevalence of comorbidity and impact on survival among persons with lung, colorectal, breast, or prostate cancer. Cancer. 2014;120(9):1290–1314. - PMC - PubMed
    1. Prenen H, Van Cutsem E. Oncological management of unresectable liver metastases. Dig Dis. 2012;30(Suppl 2):137–142. - PubMed
    1. Manfredi S, Lepage C, Hatem C, Coatmeur O, Faivre J, Bouvier AM. Epidemiology and management of liver metastases from colorectal cancer. Ann Surg. 2006;244(2):254–259. - PMC - PubMed